In recent years, AAV manufacturing processes have evolved significantly to not only address the need for later-stage clinical and commercial supplies, but also to address regulatory concerns around ...

The overall process for developing and manufacturing vaccines and cell and gene therapies (CGTs) is challenging and resource intensive because it involves complex and variable raw materials, demanding ...